Show simple item record

dc.contributor.authorHuddart, RA
dc.contributor.authorSiefker-Radtke, AO
dc.contributor.authorBalar, AV
dc.contributor.authorBilen, MA
dc.contributor.authorPowles, T
dc.contributor.authorBamias, A
dc.contributor.authorCastellano, D
dc.contributor.authorKhalil, MF
dc.contributor.authorVan Der Heijden, MS
dc.contributor.authorKoshkin, VS
dc.contributor.authorPook, DW
dc.contributor.authorÖzgüroğlu, M
dc.contributor.authorSantiago, L
dc.contributor.authorZhong, B
dc.contributor.authorChien, D
dc.contributor.authorLin, W
dc.contributor.authorTagliaferri, MA
dc.contributor.authorLoriot, Y
dc.date.accessioned2020-10-12T11:35:06Z
dc.date.issued2020-09-17
dc.identifier.citationFuture oncology (London, England), 2020
dc.identifier.issn1479-6694
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4140
dc.identifier.eissn1744-8301
dc.identifier.doi10.2217/fon-2020-0795
dc.description.abstractThe choice of first-line therapy for patients with metastatic urothelial cancer (mUC) is based on cisplatin-eligibility and programmed death-ligand 1 (PD-L1) status. For patients with mUC who are ineligible for cisplatin and with low PD-L1 expression, chemotherapy-based regimens are the only approved first-line option. In a Phase I/II trial of the chemotherapy-free regimen, bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab, patients with locally advanced or mUC experienced tumor responses regardless of baseline PD-L1 expression (objective response rates: 50 and 45% in patients with PD-L1-positive and -negative tumors, respectively). The Phase II PIVOT-10 study (NCT03785925), evaluates efficacy and safety of first-line BEMPEG plus nivolumab in cisplatin-ineligible patients with locally advanced or mUC. Most patients will have low PD-L1 expression. Primary end point: objective response rates (including complete response).
dc.formatPrint-Electronic
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titlePIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer.
dc.typeJournal Article
rioxxterms.versionofrecord10.2217/fon-2020-0795
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2020-09-17
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfFuture oncology (London, England)
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.publication-statusPublished
pubs.embargo.termsNot known
icr.researchteamClinical Academic Radiotherapy (Huddart)en_US
dc.contributor.icrauthorHuddart, Roberten


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0